Search Results
Your search for all items matches 30161 pages
Showing 51 - 100Risk of Major Psychiatric Disorders Among Survivors of Childhood and Adolescent Cancers
In a Taiwanese study reported in the Journal of Clinical Oncology, Hsu et al found that survivors of childhood and adolescent cancers were at a significantly increased risk of multiple major psychiatric disorders compared to those without cancer. Study Details The study used data from a...
Receiving Chemotherapy in the Afternoon May Improve Treatment Outcomes in Some Patients With DLBCL
Utilizing chronochemotherapy—a method aimed at delivering chemotherapy at a time when the body is least vulnerable to its harmful effects and when the cancer cells are at their most vulnerable—may improve the outcomes of some patients with diffuse large B-cell lymphoma (DLBCL), according to a novel ...
Emily C. Daugherty, MD, on FLASH Radiotherapy: Efficacy and Safety Results From the First-in-Human Study
Emily C. Daugherty, MD, of the University of Cincinnati, discusses results from the FAST-01 study, which showed that FLASH proton radiotherapy, delivered at ultra-high–dose rates, may be efficacious, with adverse events comparable to conventional dose-rate treatment of patients with cancer....
Undaunted
Soon after my marriage, in 2003, I noticed swelling in the glands around my throat. Although I otherwise felt fine, I went to see my primary care physician for a checkup and a blood test. The results of the test showed that I had an abnormally high number of lymphocytes circulating in my...
Atrium Health and Wake Forest University School of Medicine Cancer Program Appoint New Director
Atrium Health recently announced that Ruben A. Mesa, MD, FACP, has been named President and Executive Director of its cancer service line—which includes both Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center—and Vice Dean for Cancer Programs at...
Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care
Most of us have felt our stomachs sink as we opened a patient’s radiology or laboratory report and realized the patient faced a grave situation. If we’re lucky, we have a couple of days before a scheduled patient appointment to prepare ourselves to deliver that bad news. Other times, we may have...
Inaugural Recipients of the Lubin Family Foundation Scholar Award Named
The four inaugural recipients of the Lubin Family Foundation Scholar Award have been announced by Dana-Farber Cancer Institute and the Richard K. Lubin Family Foundation. Lubin Scholars are among the most promising physician-scientists pursuing cancer-relevant basic or translational...
Remembering Breast Cancer Pioneer Isaac Craig Henderson, MD
Isaac Craig Henderson, MD, passed away at the age of 81 at his home in San Francisco on December 26, 2022, after a brief illness. Dr. Henderson was an internationally known medical oncologist who specialized in breast cancer, beginning his career at Harvard’s then-designated Sidney Farber Cancer...
Expert Point of View: Nancy Chan, MD
Nancy Chan, MD, Director of Breast Cancer Clinical Research at NYU Langone’s Perlmutter Cancer Center, New York, commented on the monarchE analysis for The ASCO Post. She noted that the study investigated the addition of adjuvant abemaciclib (an oral CDK4/6 inhibitor) to endocrine therapy in a...
Update From monarchE: Benefit of Abemaciclib Increases Over Time in Early-Stage Breast Cancer
Results of a planned interim overall survival analysis of the phase III monarchE trial offered further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk disease, according to Stephen R.D....
Expert Point of View: Jaime A. Suarez-Londono, MD
Jaime A. Suarez-Londono, MD, a medical oncologist at NYU Langone’s Perlmutter Cancer Center and Assistant Professor of Medicine at NYU Grossman School of Medicine, said the results of the ASAP study provide a basis for discussion with the transplant team. “The landscape of treatment of acute...
Intensive Remission Induction Chemotherapy vs Less Intensive Approach Prior to Transplant for Relapsed/Refractory AML
Intensive salvage therapy with the goal of achieving complete remission prior to allogeneic hematopoietic cell transplantation (alloHCT) may not be necessary in some patients with relapsed or refractory acute myeloid leukemia (AML), according to the results of the phase III ASAP trial presented at...
Andrea Schietinger, PhD, to Present 2023 AACR–Irving Weinstein Foundation Distinguished Lecture
The American Association for Cancer Research (AACR) will award the 19th AACR–Irving Weinstein Foundation Distinguished Lectureship to Andrea Schietinger, PhD, during the 2023 AACR Annual Meeting, held April 14–19, in Orlando, Florida. Dr. Schietinger, an associate member of the Immunology Program...
KU Medical Center Researchers Receive R01 Grant From NCI to Improve Access to Targeted Cancer Treatments for Rural Patients
Precision medicine has revolutionized cancer treatment—but only for patients who have access to treatments. Nearly 2 million people in the United States are diagnosed each year with cancer, but access to targeted treatments varies widely, and only about half of the eligible people receive them,...
The Influence of Structural Racism and Poverty on Outcomes in Leukemia
In the United States, Black American patients with acute myeloid leukemia (AML) have notably worse survival outcomes compared to White patients. In addition, Black patients are less likely to receive intensive chemotherapy and undergo allogeneic stem cell transplants. Many researchers have reported ...
Northwell Receives Gift From Trustee Roy J. Zuckerberg to Create First Cancer Hospital and Cancer Campus on Long Island
Northwell Health recently announced a gift from longtime trustee Roy J. Zuckerberg to create the R.J. Zuckerberg Cancer Hospital at Long Island Jewish (LIJ) Medical Center—Long Island’s first cancer hospital—and to establish the R.J. Zuckerberg Cancer Center, Northwell’s largest ambulatory cancer...
How Experts Treat Mantle Cell Lymphoma in First Complete Response
Options are growing in the treatment of mantle cell lymphoma after complete response. At the 2022 Pan Pacific Lymphoma Conference,1 the use of these newer strategies in older patients was discussed by Brad S. Kahl, MD, Professor of Medicine and Director of the Lymphoma Service at Washington...
Determining the Role of Muscadine Grape Skin Extract in Treating Prostate Cancer
Oxidative stress is a key factor in the development of many diseases including cancer. Antioxidants prevent cellular damage by neutralizing free radicals and are being investigated as potential therapeutic strategies against cancer. In this installment of The ASCO Post’s Integrative Oncology...
NRG Oncology Announces Leadership of New DEI Committee and New Vice Chair for Ancillary Projects Committee
NRG Oncology, a National Cancer Institute (NCI) National Clinical Trials Network (NTCN) group focused on improving outcomes for adults with cancer through international clinical research, recently announced the appointed leadership of the organization’s new Diversity, Equity, and Inclusion (DEI)...
Expert Point of View: Antonio González-Martín, MD, PhD
Abstract discussant of the NORA trial, Antonio González-Martín, MD, PhD, Director of the Department of Medical Oncology at Clinica Universidad de Navarra, Madrid, said that despite the results of this ad hoc interim analysis, “the jury is still out” regarding the overall survival benefit of PARP...
Phase III NORA Trial: Niraparib Maintenance Shows Overall Survival Trend in Platinum-Sensitive Recurrent Ovarian Cancer
Maintenance therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor may do more than just delay disease progression for patients with platinum-sensitive, relapsed ovarian cancer; it might also improve overall survival, according to data presented during the December 2022 European Society for...
Being on the Other Side: An Oncologist’s Perspective on Grieving
As an oncologist, I had cared for patients facing grave illness and death. I imagined the loss of loved ones and expected grief to be an unbearable sadness, most poignant in the earliest days and lessening with time. I somehow expected that counseling people who grieved would make me more prepared. ...
A Serendipitous Opportunity Steers a Theater Major Into Oncology
Lymphoma expert Jeremy S. Abramson, MD, was born in Westchester County, New York, but soon after, his family relocated to Bergen County, New Jersey, where he spent his formative years. “I attended Tenafly High School and had dual passions: one was the natural sciences and the other on the...
Expert Point of View: Urvi A. Shah, MD
Urvi A. Shah, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor at Weill Cornell Medicine, New York, moderated the session where the MagnetisMM trial updates1,2 were reported and was interviewed by The ASCO Post. Elranatamab vs Teclistamab Dr. Shah noted...
Elranatamab Induces Responses in Many Patients With Resistant Multiple Myeloma in Phase II Trial
The promise of bispecific monoclonal antibodies in multiple myeloma continues to heighten as yet another one appears to be active. In a study reported at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition,1 almost two-thirds of patients with triple-refractory disease who...
Maureen Murphy, PhD, Named Deputy Director of the Wistar Institute’s Ellen and Ronald Caplan Cancer Center
The Ellen and Ronald Caplan Cancer Center at The Wistar Institute, Philadelphia, has announced the appointment of the Ira Brind Endowed Professor, Maureen Murphy, PhD, as Deputy Director. Dr. Murphy will guide the growth of the Cancer Center through expanding research initiatives and collaboration, ...
First Adenoviral Vector–Based Gene Therapy for High-Risk BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
On December 16, 2022, nadofaragene firadenovec-vncg, an adenoviral vector–based gene therapy, was approved for patients with high-risk bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.1 Supporting Efficacy Data...
Significant Benefit With Addition of Daratumumab to Bortezomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma
As reported in the Journal of Clinical Oncology by Pieter Sonneveld, MD, PhD, of Erasmus MC Cancer Institute, Rotterdam, the Netherlands, and colleagues, the final overall survival analysis of the phase III CASTOR trial has shown a significant benefit of the addition of daratumumab to...
Cardiovascular Events Before and After Initiation of Immune Checkpoint Inhibitor Therapy for Cancer
In a study reported in JACC: CardioOncology, Lavanya Kondapalli, MD, of the University of Colorado School of Medicine, Aurora, and colleagues found that cardiovascular events common in the general population were observed both prior to and after the initiation of immune checkpoint inhibitor therapy ...
Risks of Cardiovascular and Immune-Related Adverse Events in Immune Checkpoint Inhibitor Therapy
In a single academic hospital network retrospective case-control study reported in JACC:CardioOncology, Charlotte Lee, MD, of Columbia University Irving Medical Center, New York, along with senior author Tomas Neilan, MD, MPH, of Massachusetts General Hospital and colleagues found that patients...
Study Explores the Addition of First-Line Atezolizumab in BRAF V600–Mutant Advanced Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Pascale, Naples, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but...
Manik A. Amin, MD, on Novel Immune Therapies in GI Cancers: What’s on the Horizon?
Manik A. Amin, MD, of Dartmouth Cancer Center, discusses the future of immunotherapy in gastrointestinal cancers, the challenges of creating effective adoptive cell therapies, and the next generation of immune checkpoint inhibitors.
Nick Pavlakis, PhD, MBBS, on Gastroesophageal Cancer: New Findings on the Use of Regorafenib
Nick Pavlakis, PhD, MBBS, of Australia’s Royal North Shore Hospital, discusses phase III findings from the INTEGRATE IIa study of regorafenib vs placebo in refractory advanced gastroesophageal cancer. The trial provides a platform for the investigation of combination therapy with an immune...
Richard S. Finn, MD, on HCC: Tislelizumab vs Sorafenib, and Their Impact on Quality of Life
Richard S. Finn, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, discusses findings from the RATIONALE-301 study, which showed that patients with unresectable hepatocellular carcinoma (HCC) treated with first-line tislelizumab had better health-related...
FDA Oncology Center of Excellence Seeks Applications for New Research Funding Opportunities
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Julie A. Schneider, PhD, Associate Director for Research Strategy and Partnerships, OCE; Jennifer J. Gao, MD,...
New Study Evaluates Online Colorectal Cancer Risk Calculators
Many individuals considering screening for colorectal cancer may want information on their personal risk when making decisions about screening—such as whether to select an at-home stool-based test or colonoscopy. Investigators evaluated five online colorectal cancer risk calculators to determine...
Real-World Use of Idecabtagene Vicleucel for Patients With Relapsed or Refractory Multiple Myeloma
In a retrospective study of the real-world use of idecabtagene vicleucel reported in the Journal of Clinical Oncology, Hansen et al found that response rates and toxicity in patients with relapsed or refractory multiple myeloma were comparable to those in the pivotal phase II KarMMa trial; the...
Interventions to Improve Skin Cancer Surveillance in Childhood Cancer Survivors Who Received Radiotherapy
In a study (Advancing Survivors Knowledge; ASK) reported in the Journal of Clinical Oncology, Geller et al found that three patient- and patient/physician-based interventions to improve skin cancer surveillance among childhood cancer survivors treated with radiotherapy resulted in increased rates...
Trends in Stage, Treatment, and Outcomes in Rectal Adenocarcinoma in the United States: 2004 to 2019
In a retrospective, observational case series study reported in JAMA Oncology, Emile et al identified changes in the stage at diagnosis, treatments, and outcomes in U.S. patients with rectal adenocarcinoma diagnosed between 2004 and 2019. Study Details The study used National Cancer Database data...
Addition of Ultrasound to DBT for Breast Cancer Screening in Patients With Dense Breasts
In the DBTUST study reported in the Journal of Clinical Oncology, Berg et al found that the addition of screening ultrasound to digital breast tomosynthesis (DBT) improved detection of cancer in patients with dense breasts—but also increased the rate of false-positive findings. Study Details In the ...
Josep Tabernero, MD, PhD, on Colorectal Cancer: Recent Data on Treatment With Trifluridine and Tipiracil Plus Bevacizumab
Josep Tabernero, MD, PhD, of Spain’s Vall d’Hebron Institute of Oncology, discusses phase III findings from the SUNLIGHT study, which showed that trifluridine and tipiracil (FTD/TPI) plus bevacizumab resulted in improved outcomes compared with FTD/TPI alone in patients with refractory metastatic...
Rachna T. Shroff, MD, on Biliary Tract Cancers: Recent Findings on Use of Gemcitabine, Cisplatin, and Nab-paclitaxel
Rachna T. Shroff, MD, of the University of Arizona Cancer Center, discusses phase III results from the SWOG 1815 study, which compared gemcitabine, cisplatin, and nab-paclitaxel vs gemcitabine and cisplatin in patients with newly diagnosed, advanced biliary tract cancers. Although adding...
NAPOLI-3: First-Line NALIRIFOX Regimen Improves Overall Survival in Metastatic Pancreatic Cancer
In the phase III NAPOLI-3 trial in previously untreated patients with metastatic pancreatic cancer, the NALIRIFOX regimen significantly improved overall survival and progression-free survival over nab-paclitaxel plus gemcitabine. NALIRIFOX contains liposomal irinotecan, fluorouracil, leucovorin,...
Combination of Botensilimab and Balstilimab Shows Activity in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
A combination of the next-generation immunotherapies botensilimab and balstilimab showed clinical activity in treating patients with refractory metastatic microsatellite-stable (MSS) colorectal cancer, according to new findings presented by El-Khoueiry et al at the 2023 ASCO Gastrointestinal...
Addition of Veliparib to Cisplatin in Advanced Triple-Negative Breast Cancer With BRCA-Like and Non–BRCA-Like Phenotype
In a phase II trial (S1416) reported in The Lancet Oncology, Rodler et al found that the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to cisplatin significantly improved progression-free survival in patients with germline BRCA1/2 wild-type advanced triple-negative breast...
Ibrutinib in the First-Line Treatment of Chronic GVHD
As reported in the Journal of Clinical Oncology by Miklos et al, the phase III iNTEGRATE trial showed no benefit of the addition of ibrutinib to prednisone in the first-line treatment of moderate or severe chronic graft-vs-host disease (GVHD) after allogeneic hematopoietic cell transplantation....
Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation: Long-Term Cosmetic Results and Toxicity
As reported in the Journal of Clinical Oncology by Meduri et al, a 5-year analysis from the phase III IRMA trial has shown higher rates of adverse cosmesis and some late toxicities with external-beam accelerated partial-breast irradiation (APBI) vs whole-breast irradiation (WBI) in women with stage ...
Lenvatinib and Pembrolizumab in Previously Treated Patients With Advanced Endometrial Carcinoma: Update of Study 111/KEYNOTE-146
In an analysis reported in the Journal of Clinical Oncology, Vicky Makker, MD, and colleagues provided updated findings from the phase Ib/II Study 111/KEYNOTE-146 trial of lenvatinib and pembrolizumab in previously treated patients with advanced endometrial carcinoma. The study supported the...
Robin Zon Elected ASCO President for 2024–2025 Term; Other Leadership Positions Filled
ASCO has elected Robin Zon, MD, FACP, FASCO, a long-time member and volunteer, as its President beginning in June 2024. Dr. Zon will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 5, 2023. Five additional members were elected to the ASCO...
Former ASCO President Monica Bertagnolli Welcomed as NCI Director in Capitol Hill Reception
On December 7, 2022, Association for Clinical Oncology (ASCO) Chief Medical Officer and Executive Vice President Julie Gralow MD, FACP, FASCO, attended a reception on Capitol Hill hosted by the One Voice Against Cancer Coalition and the House Cancer Caucus, to welcome former ASCO President Monica...
